Key result
Interferon-free DAAs fail to resolve mixed cryoglobulinaemia vasculitis despite HCV eradication.
Why the study?
Limited data exist on the efficacy of interferon-free direct-acting antiviral regimens in patients with hepatitis C virus-related mixed cryoglobulinaemia vasculitis.
Do all-oral direct-acting antiviral combinations improve clinical and laboratory manifestations in patients with HCV-related mixed cryoglobulinaemia vasculitis?
Do all-oral direct-acting antiviral combinations improve clinical and laboratory manifestations in patients with HCV-related mixed cryoglobulinaemia vasculitis?
Answers are grounded in this paper and cite their sources.
All-oral direct-acting antiviral therapy may eradicate HCV but fail to resolve mixed cryoglobulinaemia vasculitis in some patients.
Sir , Mixed cryoglobulinaemia vasculitis (MCV) is a systemic vasculitis of the small and medium-sized vessels caused by HCV in > 80% of cases. It is characterized by the presence of circulating cryoprecipitable immune complexes composed of polyclonal IgGs and mono- or polyclonal IgMs with RF activity. The disease expression is variable, ranging from purpura, arthralgia and asthenia to more serious lesions with neurological and renal involvement [ 1 ]. Unlike other viral-induced vasculitides in which the infectious agent cannot be eradicated, HCV RNA clearance following antiviral treatment with peginterferon (pegIFN)/ribavirin has been associated with the disappearance or at least an improvement of the clinical and laboratory manifestations of HCV-related MCV (HCV-MCV) in most cases [ 2–4 ]. New highly potent and well-tolerated direct-acting antivirals (DAAs) used in IFN-free regimens have proven to be effective in chronic hepatitis C, with sustained virological response (SVR) rates >90%; however, there are limited data on their efficacy in HCV-MCV patients [ 5 , 6 ]. This report describes the results of treatment with different all-oral DAA combinations in seven patients with HCV-MCV. The study was approved by the Institutional Ethics Committee (L. Sacco Hospital) and all the patients provided their informed consent.
No takes yet. Share an insight, caveat, or question.
Sollima et al. (2016) conducted a letter in HCV-related mixed cryoglobulinaemia vasculitis (HCV-MCV) (n=7). All-oral direct-acting antiviral (DAA) combinations was evaluated. Mixed cryoglobulinaemia vasculitis persisted despite hepatitis C virus eradication after treatment with interferon-free all-oral direct-acting antiviral combinations in seven patients.
Synapse has enriched 10 related papers. Consider them for comparative context: